News & Updates

Show Multimedia Only
Chemo plus immunotherapy improves survival in advanced endometrial cancer
Chemo plus immunotherapy improves survival in advanced endometrial cancer
09 Jun 2024

Adding immunotherapy to the first-line treatment for advanced and metastatic endometrial cancer may significantly improve some oncologic outcomes, particularly within the mismatch repair deficiency/microsatellite instability-hypermutated (MMRd/MSI-H) subset, suggests a study.

Chemo plus immunotherapy improves survival in advanced endometrial cancer
09 Jun 2024
Bispecific antibody delivers positive results in relapsed, refractory multiple myeloma
Bispecific antibody delivers positive results in relapsed, refractory multiple myeloma
08 Jun 2024 byJairia Dela Cruz

A large percentage of patients with relapsed/refractory multiple myeloma (RRMM) respond to the bispecific antibody linvoseltamab, with deep and durable responses seen even in the high-risk subgroups, according to data from the phase I/II LINKER-MM1 trial.

Bispecific antibody delivers positive results in relapsed, refractory multiple myeloma
08 Jun 2024